Vigil Neuroscience (VIGL) to Release Quarterly Earnings on Tuesday

Vigil Neuroscience (NASDAQ:VIGL) is expected to announce its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). On average, analysts expect Vigil Neuroscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vigil Neuroscience Price Performance

Shares of NASDAQ:VIGL opened at $1.89 on Monday. Vigil Neuroscience has a 1-year low of $1.49 and a 1-year high of $6.06. The stock has a market cap of $88.21 million, a P/E ratio of -0.92 and a beta of 1.82. The firm has a fifty day moving average price of $2.35 and a 200 day moving average price of $2.73.

Analysts Set New Price Targets

VIGL has been the subject of several recent research reports. William Blair initiated coverage on shares of Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. HC Wainwright lowered their target price on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 14th. JMP Securities restated a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, Wedbush decreased their price target on Vigil Neuroscience from $24.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, March 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Vigil Neuroscience has an average rating of “Buy” and a consensus price target of $16.25.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.